- Home
- EXAS vs NDSN Comparison
EXAS vs NDSN Comparison
Compare EXAS & NDSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- NDSN
- Stock Information
- Founded
- EXAS 1995
- NDSN 1935
- Country
- EXAS United States
- NDSN United States
- Employees
- EXAS N/A
- NDSN N/A
- Industry
- EXAS Medical Specialities
- NDSN Industrial Machinery/Components
- Sector
- EXAS Health Care
- NDSN Industrials
- Exchange
- EXAS Nasdaq
- NDSN Nasdaq
- Market Cap
- EXAS 10.6B
- NDSN 12.8B
- IPO Year
- EXAS N/A
- NDSN N/A
- Fundamental
- Price
- EXAS $57.01
- NDSN $234.50
- Analyst Decision
- EXAS Strong Buy
- NDSN Strong Buy
- Analyst Count
- EXAS 21
- NDSN 6
- Target Price
- EXAS $67.86
- NDSN $265.33
- AVG Volume (30 Days)
- EXAS 2.3M
- NDSN 290.1K
- Earning Date
- EXAS 11-04-2025
- NDSN 08-20-2025
- Dividend Yield
- EXAS N/A
- NDSN 1.41%
- EPS Growth
- EXAS N/A
- NDSN N/A
- EPS
- EXAS N/A
- NDSN 7.95
- Revenue
- EXAS $2,939,949,000.00
- NDSN $2,784,349,000.00
- Revenue This Year
- EXAS $16.68
- NDSN $6.32
- Revenue Next Year
- EXAS $12.08
- NDSN $4.51
- P/E Ratio
- EXAS N/A
- NDSN $29.36
- Revenue Growth
- EXAS 12.55
- NDSN 4.49
- 52 Week Low
- EXAS $38.81
- NDSN $165.03
- 52 Week High
- EXAS $72.83
- NDSN $266.86
- Technical
- Relative Strength Index (RSI)
- EXAS 68.53
- NDSN 65.37
- Support Level
- EXAS $52.85
- NDSN $224.27
- Resistance Level
- EXAS $54.74
- NDSN $228.02
- Average True Range (ATR)
- EXAS 1.40
- NDSN 4.07
- MACD
- EXAS 0.17
- NDSN 0.75
- Stochastic Oscillator
- EXAS 93.39
- NDSN 93.93
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.